Which has higher earnings and valuation, ONC or KRYS?

BeOne Medicines has higher revenue and earnings than Krystal Biotech. Krystal Biotech is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeOne Medicines $5.34B 6.49 $286.93M $4.47 70.70 Krystal Biotech $389.13M 25.84 $204.83M $7.48 45.60

Does the media prefer ONC or KRYS?

In the previous week, Krystal Biotech had 4 more articles in the media than BeOne Medicines. MarketBeat recorded 18 mentions for Krystal Biotech and 14 mentions for BeOne Medicines. Krystal Biotech's average media sentiment score of 1.17 beat BeOne Medicines' score of 0.90 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 13 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TEVA or KRYS?

In the previous week, Teva Pharmaceutical Industries had 30 more articles in the media than Krystal Biotech. MarketBeat recorded 48 mentions for Teva Pharmaceutical Industries and 18 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.17 beat Teva Pharmaceutical Industries' score of 0.77 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 26 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Krystal Biotech 13 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ROIV or KRYS?

Krystal Biotech has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roivant Sciences $8.26M 2,952.84 -$299.77M -$0.60 N/A Krystal Biotech $389.13M 25.84 $204.83M $7.48 45.60

Does the media prefer ROIV or KRYS?

In the previous week, Krystal Biotech had 2 more articles in the media than Roivant Sciences. MarketBeat recorded 18 mentions for Krystal Biotech and 16 mentions for Roivant Sciences. Krystal Biotech's average media sentiment score of 1.17 beat Roivant Sciences' score of 1.16 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 13 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 13 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, INSM or KRYS?

Krystal Biotech has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 35.24 -$1.28B -$5.75 N/A Krystal Biotech $389.13M 25.84 $204.83M $7.48 45.60

Is INSM or KRYS more profitable?

Krystal Biotech has a net margin of 53.92% compared to Insmed's net margin of -144.44%. Krystal Biotech's return on equity of 19.25% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% Krystal Biotech 53.92% 19.25% 17.62%

Does the media refer more to INSM or KRYS?

In the previous week, Krystal Biotech had 5 more articles in the media than Insmed. MarketBeat recorded 18 mentions for Krystal Biotech and 13 mentions for Insmed. Insmed's average media sentiment score of 1.30 beat Krystal Biotech's score of 1.17 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 13 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KRYS or BNTX?

In the previous week, Krystal Biotech had 12 more articles in the media than BioNTech. MarketBeat recorded 18 mentions for Krystal Biotech and 6 mentions for BioNTech. Krystal Biotech's average media sentiment score of 1.17 beat BioNTech's score of 0.86 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 13 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Live Earnings Conference Call: Krystal Biotech will host a live Q2 2026 earnings call on August 3, 2026 at 8:30AM ET. Get details.

Krystal Biotech (KRYS) Competitors

$341.12 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$339.40 -1.72 (-0.50%)

As of 07/31/2026 07:40 PM Eastern

Compare

KRYS vs. ONC, TEVA, ROIV, INSM, and BNTX

Should you buy Krystal Biotech stock or one of its competitors? MarketBeat compares Krystal Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Krystal Biotech include BeOne Medicines (ONC), Teva Pharmaceutical Industries (TEVA), Roivant Sciences (ROIV), Insmed (INSM), and BioNTech (BNTX).

How does Krystal Biotech compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Krystal Biotech (NASDAQ:KRYS) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

BeOne Medicines has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

Krystal Biotech has a net margin of 53.92% compared to BeOne Medicines' net margin of 8.94%. Krystal Biotech's return on equity of 19.25% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Krystal Biotech	53.92%	19.25%	17.62%

BeOne Medicines presently has a consensus price target of $394.00, suggesting a potential upside of 24.68%. Krystal Biotech has a consensus price target of $360.67, suggesting a potential upside of 5.73%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.88
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, Krystal Biotech had 4 more articles in the media than BeOne Medicines. MarketBeat recorded 18 mentions for Krystal Biotech and 14 mentions for BeOne Medicines. Krystal Biotech's average media sentiment score of 1.17 beat BeOne Medicines' score of 0.90 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	13 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has higher revenue and earnings than Krystal Biotech. Krystal Biotech is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.49	$286.93M	$4.47	70.70
Krystal Biotech	$389.13M	25.84	$204.83M	$7.48	45.60

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 13.1% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Krystal Biotech beats BeOne Medicines on 10 of the 17 factors compared between the two stocks.

How does Krystal Biotech compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Krystal Biotech (NASDAQ:KRYS) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Teva Pharmaceutical Industries has higher revenue and earnings than Krystal Biotech. Krystal Biotech is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.33	$1.41B	$0.60	58.41
Krystal Biotech	$389.13M	25.84	$204.83M	$7.48	45.60

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Teva Pharmaceutical Industries has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Krystal Biotech has a net margin of 53.92% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Krystal Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%
Krystal Biotech	53.92%	19.25%	17.62%

Teva Pharmaceutical Industries presently has a consensus price target of $42.00, indicating a potential upside of 19.84%. Krystal Biotech has a consensus price target of $360.67, indicating a potential upside of 5.73%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, Teva Pharmaceutical Industries had 30 more articles in the media than Krystal Biotech. MarketBeat recorded 48 mentions for Teva Pharmaceutical Industries and 18 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.17 beat Teva Pharmaceutical Industries' score of 0.77 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	26 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Krystal Biotech	13 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Teva Pharmaceutical Industries and Krystal Biotech tied by winning 8 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Krystal Biotech (NASDAQ:KRYS) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Roivant Sciences currently has a consensus target price of $33.59, indicating a potential downside of 0.94%. Krystal Biotech has a consensus target price of $360.67, indicating a potential upside of 5.73%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Krystal Biotech is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Krystal Biotech has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,952.84	-$299.77M	-$0.60	N/A
Krystal Biotech	$389.13M	25.84	$204.83M	$7.48	45.60

Roivant Sciences has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

Krystal Biotech has a net margin of 53.92% compared to Roivant Sciences' net margin of -3,629.19%. Krystal Biotech's return on equity of 19.25% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Krystal Biotech	53.92%	19.25%	17.62%

In the previous week, Krystal Biotech had 2 more articles in the media than Roivant Sciences. MarketBeat recorded 18 mentions for Krystal Biotech and 16 mentions for Roivant Sciences. Krystal Biotech's average media sentiment score of 1.17 beat Roivant Sciences' score of 1.16 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	13 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	13 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Krystal Biotech beats Roivant Sciences on 13 of the 15 factors compared between the two stocks.

How does Krystal Biotech compare to Insmed?

Insmed (NASDAQ:INSM) and Krystal Biotech (NASDAQ:KRYS) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Insmed has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

Krystal Biotech has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	35.24	-$1.28B	-$5.75	N/A
Krystal Biotech	$389.13M	25.84	$204.83M	$7.48	45.60

Insmed currently has a consensus target price of $209.35, suggesting a potential upside of 112.32%. Krystal Biotech has a consensus target price of $360.67, suggesting a potential upside of 5.73%. Given Insmed's stronger consensus rating and higher probable upside, equities analysts clearly believe Insmed is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

86.3% of Krystal Biotech shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Krystal Biotech has a net margin of 53.92% compared to Insmed's net margin of -144.44%. Krystal Biotech's return on equity of 19.25% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Krystal Biotech	53.92%	19.25%	17.62%

In the previous week, Krystal Biotech had 5 more articles in the media than Insmed. MarketBeat recorded 18 mentions for Krystal Biotech and 13 mentions for Insmed. Insmed's average media sentiment score of 1.30 beat Krystal Biotech's score of 1.17 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	13 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Krystal Biotech beats Insmed on 9 of the 17 factors compared between the two stocks.

How does Krystal Biotech compare to BioNTech?

Krystal Biotech (NASDAQ:KRYS) and BioNTech (NASDAQ:BNTX) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Krystal Biotech has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Krystal Biotech has a net margin of 53.92% compared to BioNTech's net margin of -44.39%. Krystal Biotech's return on equity of 19.25% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
BioNTech	-44.39%	-5.30%	-4.62%

Krystal Biotech presently has a consensus target price of $360.67, suggesting a potential upside of 5.73%. BioNTech has a consensus target price of $129.13, suggesting a potential upside of 42.55%. Given BioNTech's higher possible upside, analysts clearly believe BioNTech is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

In the previous week, Krystal Biotech had 12 more articles in the media than BioNTech. MarketBeat recorded 18 mentions for Krystal Biotech and 6 mentions for BioNTech. Krystal Biotech's average media sentiment score of 1.17 beat BioNTech's score of 0.86 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	13 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	25.84	$204.83M	$7.48	45.60
BioNTech	$3.25B	7.06	-$1.29B	-$5.88	N/A

Summary

Krystal Biotech beats BioNTech on 11 of the 17 factors compared between the two stocks.

Get Krystal Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KRYS vs. The Competition

Export

Metric	Krystal Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.06B	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	45.60	7.38	282.27	24.66
Price / Sales	25.84	1,273.79	590.91	92.54
Price / Cash	46.79	44.80	28.60	46.71
Price / Book	8.11	16.78	10.93	6.07
Net Income	$204.83M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-3.04%	-1.82%	-0.64%	-0.42%
1 Month Performance	-9.05%	-8.45%	-3.78%	-4.80%
1 Year Performance	117.30%	48.33%	61.99%	18.61%

Krystal Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KRYS Krystal Biotech	3.2644 of 5 stars	$341.12 flat	$360.67 +5.7%	+117.3%	$10.06B	$389.13M	45.60	210	News Coverage Positive News Gap Up
ONC BeOne Medicines	4.6379 of 5 stars	$325.90 flat	$394.00 +20.9%	+5.7%	$35.76B	$5.34B	72.91	12,000	Upcoming Earnings
TEVA Teva Pharmaceutical Industries	4.1301 of 5 stars	$31.08 +0.9%	$41.78 +34.4%	+127.9%	$35.43B	$17.26B	23.37	33,950	Trending News Earnings Report Analyst Upgrade
ROIV Roivant Sciences	1.5764 of 5 stars	$34.72 -0.8%	$33.59 -3.3%	+199.8%	$25.18B	$8.26M	N/A	860	Positive News Upcoming Earnings Analyst Forecast
INSM Insmed	3.8307 of 5 stars	$104.73 -2.0%	$209.13 +99.7%	-9.3%	$23.18B	$606.42M	N/A	1,664	Positive News Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KRYS) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Krystal Biotech (KRYS) Competitors

KRYS vs. ONC, TEVA, ROIV, INSM, and BNTX

How does Krystal Biotech compare to BeOne Medicines?

Summary

How does Krystal Biotech compare to Teva Pharmaceutical Industries?

Summary

How does Krystal Biotech compare to Roivant Sciences?

Summary

How does Krystal Biotech compare to Insmed?

Summary

How does Krystal Biotech compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Krystal Biotech (KRYS) Competitors

KRYS vs. ONC, TEVA, ROIV, INSM, and BNTX

How does Krystal Biotech compare to BeOne Medicines?

Which has more volatility & risk, ONC or KRYS?

Is ONC or KRYS more profitable?

Do analysts recommend ONC or KRYS?

Does the media prefer ONC or KRYS?

Which has higher earnings and valuation, ONC or KRYS?

Do institutionals & insiders hold more shares of ONC or KRYS?

Summary

How does Krystal Biotech compare to Teva Pharmaceutical Industries?

Which has preferable valuation and earnings, TEVA or KRYS?

Do institutionals and insiders believe in TEVA or KRYS?

Which has more volatility & risk, TEVA or KRYS?

Is TEVA or KRYS more profitable?

Do analysts rate TEVA or KRYS?

Does the media refer more to TEVA or KRYS?

Summary

How does Krystal Biotech compare to Roivant Sciences?

Do institutionals & insiders believe in ROIV or KRYS?

Do analysts rate ROIV or KRYS?

Which has stronger earnings & valuation, ROIV or KRYS?

Which has more volatility and risk, ROIV or KRYS?

Is ROIV or KRYS more profitable?

Does the media prefer ROIV or KRYS?

Summary

How does Krystal Biotech compare to Insmed?

Which has more volatility and risk, INSM or KRYS?

Which has better earnings and valuation, INSM or KRYS?

Do analysts prefer INSM or KRYS?

Do institutionals and insiders have more ownership in INSM or KRYS?

Is INSM or KRYS more profitable?

Does the media refer more to INSM or KRYS?

Summary

How does Krystal Biotech compare to BioNTech?

Which has more risk & volatility, KRYS or BNTX?

Do insiders and institutionals hold more shares of KRYS or BNTX?

Is KRYS or BNTX more profitable?

Do analysts prefer KRYS or BNTX?

Does the media favor KRYS or BNTX?

Which has stronger valuation and earnings, KRYS or BNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools